CPT31 / Navigen - LARVOL DELTA

Electron tomography visualization of HIV-1 virions trapped by fusion inhibitors to host cells in infected tissues. (PubMed, J Virol) - "The findings of trapped HIV-1 virions in all tissues examined demonstrate a wide distribution of the CPT31 inhibitor, a desirable property for a potential therapeutic. In addition, the presence of virions trapped by spokes, particularly in vascular endothelial cells, demonstrates that the fusion inhibitors can be used as markers for potential HIV-1-target cells within tissues, facilitating the mapping of HIV-1 target cells within the complex cellular milieu of infected tissues."

Journal • Human Immunodeficiency Virus • Infectious Disease • CD4 • CXCR4

Electron tomography visualization of HIV-1 virions trapped by fusion inhibitors to host cells in infected tissues. (PubMed, bioRxiv) - "The finding of trapped HIV-1 virions in all tissues examined demonstrates a wide distribution of the CPT31 inhibitor, a desirable property for a potential therapeutic. In addition, the presence of virions trapped by spokes, particularly in vascular endothelial cells, demonstrates that fusion inhibitors can be used as markers for potential HIV-1-target cells within tissues, facilitating the mapping of HIV-1 target cells within the complex cellular milieu of infected tissues."

Journal • Human Immunodeficiency Virus • Infectious Disease • CD4 • CXCR4

A Clinical Study of the HIV Drug CPT31 in Healthy Volunteers (clinicaltrials.gov) - P1 | N=32 | Completed | Sponsor: Navigen, Inc. | Enrolling by invitation ➔ Completed | Trial completion date: Dec 2022 ➔ Apr 2021

Trial completion • Trial completion date • Human Immunodeficiency Virus • Infectious Disease

A Clinical Study of the HIV Drug CPT31 in Healthy Volunteers (clinicaltrials.gov) - P1 | N=32 | Enrolling by invitation | Sponsor: Navigen, Inc. | Trial completion date: Apr 2021 ➔ Dec 2022

Trial completion date • Human Immunodeficiency Virus • Infectious Disease

A Clinical Study of the HIV Drug CPT31 in Healthy Volunteers (clinicaltrials.gov) - P1; N=32; Enrolling by invitation; Sponsor: Navigen, Inc.

Clinical • New P1 trial • Human Immunodeficiency Virus • Infectious Disease

Prevention and treatment of SHIVAD8 infection in rhesus macaques by a potent d-peptide HIV entry inhibitor. (PubMed, Proc Natl Acad Sci U S A) - "In chronically infected animals with viremia initially controlled by combination antiretroviral therapy (cART), CPT31 monotherapy prevented viral rebound after discontinuation of cART. These data establish CPT31 as a promising candidate for HIV prevention and treatment."

Journal • Human Immunodeficiency Virus • Infectious Disease

New long-acting injectable drug might soon be a key HIV treatment (Health-e) - "A group of scientists have developed an injectable HIV drug that blocks the virus from entering cells over a longer term. The drug has been tested on non-human primates...'This is an exciting new HIV therapeutic option for both prevention and treatment, with a unique mechanism of action compared to other approved drugs,' says Professor Michael Kay, of the University of Utah. The treatment could help those struggling with drug resistance, he adds....'As a D-peptide, our hope is that CPT31 will provide extended viral suppression with a lower dose and reduced side effects,' says Welch."

Preclinical • Human Immunodeficiency Virus